To the Editor In their randomized clinical trial published recently in JAMA Oncology, Gettinger et al1 reported that the nivolumab plus ipilimumab (N+I) regimen did not provide benefit for overall survival (OS) over nivolumab alone in immunotherapy-naive patients with pretreated advanced squamous non–small cell lung cancer (SqNSCLC). However, an OS improvement was predicted for patients with tumor PD-L1 (programmed cell death 1 ligand 1) expression less than 1% and tumor mutation burden (TMB) of 10 mutations per megabase (mt/Mb) or greater.
Gil-Sierra MD, del Pilar Briceño-Casado M, Sánchez-Hidalgo M. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer. JAMA Oncol. 2022;8(4):642. doi:10.1001/jamaoncol.2021.7787
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.